MindMed to Participate in March Investor Conferences

Rhea-AI Summary

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) will participate in several investor conferences this March, showcasing its innovations in treating brain health disorders. Key events include the 34th Annual Roth Conference on March 15, the Oppenheimer Virtual Healthcare Conference on March 17, and the Maxim Virtual Growth Conference from March 28-30. Each event will feature presentations focused on the company's advancements in psychiatry and neurology. A replay of the webcasts will be available on MindMed's website for 30 days post-presentation.

News Market Reaction – MNMD

+7.92%

+7.92% Session move

In the trading session that priced this news, MNMD gained 7.92%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, March 9, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), a clinical-stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that Robert Barrow, Chief Executive Officer and Director, will participate in the following upcoming investor conferences in March:

34^th Annual Roth Conference
Format: Panel – Psychedelics: "Immunotherapy" for the Mind
Date: Tuesday, March 15 at 10:00 AM PST / 1:00 PM EST
Webcast Link: Click Here

Oppenheimer Virtual Annual Healthcare Conference
Format: Corporate Presentation
Date: Thursday, March 17 at 12:40 PM EST
Webcast Link: Click Here

Maxim Virtual Growth Conference
Format: Corporate Presentation
Date: March 28-30, 2022
Further Info: Click Here

A replay of the webcasts will be available in the "Investors" section of MindMed's website for 30 days following each of the presentations.

About MindMed

MindMed is a clinical-stage biopharmaceutical company developing novel products to treat brain health disorders, with a particular focus on psychiatry, addiction, pain and neurology. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative drug candidates, with and without acute perceptual effects, targeting the serotonin, dopamine and acetylcholine systems.

MindMed trades on the NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED.

View original content to download multimedia:https://www.prnewswire.com/news-releases/mindmed-to-participate-in-march-investor-conferences-301498744.html

SOURCE Mind Medicine (MindMed) Inc.

FAQ

What investor conferences will MindMed participate in March 2022?

MindMed will participate in the 34th Annual Roth Conference on March 15, Oppenheimer Virtual Annual Healthcare Conference on March 17, and Maxim Virtual Growth Conference from March 28-30.

What is the focus of MindMed's presentations at the conferences?

MindMed's presentations will focus on innovative treatments for brain health disorders, particularly in psychiatry and neurology.

Where can I find the webcasts of MindMed's presentations?

Replays of the webcasts will be available in the 'Investors' section of MindMed's website for 30 days following each presentation.

What is MindMed's stock symbol?

MindMed trades on the NASDAQ under the symbol MNMD.